Overview

TAK-438 Bismuth Drug Interaction Study

Status:
Completed

Trial end date:
2017-05-11

Target enrollment:

Participant gender:

Summary

To evaluate the safety, tolerability, and pharmacokinetics (PK) of quadruple therapy with bismuth, clarithromycin, amoxicillin, and TAK-438 versus quadruple therapy with bismuth, clarithromycin, amoxicillin, and lansoprazole.

Phase:

Phase 1

Details

Lead Sponsor:

Takeda

Treatments:

Amoxicillin
Bismuth
Clarithromycin
Dexlansoprazole
Lansoprazole